Navigation Links
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at,the Fourth International Conference on Tumor Microenvironment in,Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN 918864)

AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., a developer of novel cancer therapeutics, will be presenting a scientific poster at the Fourth International Conference on Tumor Microenvironment, which runs from March 6th to 10th in Florence, Italy.

The conference, hosted by the International Cancer Microenvironment Society, is a premier gathering of international cancer researchers who seek to develop cancer therapies targeting microenvironmental factors that control tumor growth and metastasis.

The poster, titled "L-DOS47 - a tumor microenvironment alkalization agent and a novel lung adenocarcinoma specific therapeutic candidate," provides a summary of selected L-DOS47 previously announced findings. Included in the poster are laboratory data showing the ability of L-DOS47 to bind to and destroy lung cancer cells alone and synergistically with selected chemotherapeutic drugs. Also being presented are mass tissue sample screening data, which show that L-DOS47 binds not only to primary lung adenocarcinoma tissues preferentially over a host of other cancerous or normal tissues, but also to metastasized cells in lymph nodes. The poster also highlights the ability of L-DOS47 to localize and concentrate in tumor tissues specifically following injection into laboratory animals

A copy of the poster will be available on Helix's website for download at http://www.helixbiopharma.com.


For additional information on the Tumor Microenvironment conference, please visit http://cancermicroenvironment.tau.ac.il/meeting-2007.html

About L-DOS47

L-DOS47 combines Helix's proprie
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
5. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
8. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
9. The Past, Present and Future of HLA Typing
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/14/2009)... THE WOODLANDS, Texas, Dec. 14 /PRNewswire/ ... investigators affiliated with US Oncology ... were presented orally at the ... , held Dec. 9-13 at the ... in San Antonio, Texas . ...
(Date:12/14/2009)... -- Perry Baromedical, international leader in Hyperbaric Chamber ... the Sigma Elite, with extended patient data capture ... is available on each monoplace chamber model currently ... Pending. ,, The Sigma Elite New "Smart Hyperbaric ... System for Each Dive Electronic (EMR) ...
(Date:12/14/2009)... CHICAGO, Dec. 14 Sword Diagnostics, Inc. ... Patent Office (USPTO) has issued patent number ... Biological Organisms using Raman Scattering" to the company. ... on improved sensitivity. ,, "The issuance of ... move forward with our continued development and commercialization," ...
Breaking Medicine Technology:US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Seattle Software Firm Claims to Cure What Ails Health Care 55353 1Seattle Software Firm Claims to Cure What Ails Health Care 55353 2GlaxoSmithKline Statement Confirming alli Safety 55350 1As Waistlines Widen Brains Shrink 55347 1As Waistlines Widen Brains Shrink 55347 2As Waistlines Widen Brains Shrink 55347 3
... WIRE)--Apr 25, 2007 - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today ... an intrinsic cell survival,pathway impacts the anticancer activity ... NF-kB, enhanced the tumor killing effects of,INGN 241 ... human tumors.,Researchers at Introgen and The University of ...
... 2007 - OSI,Pharmaceuticals, Inc. (Nasdaq: OSIP) announced ... of Clinical Oncology show that,adding Tarceva(R) (erlotinib) ... as first-line,therapy to patients with advanced pancreatic ... National Cancer Institute of Canada (NCIC),formed the ...
Other Medicine Technology:Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4
(Date:12/14/2009)... Tide of Tens of Thousands of New Chronic ... Legislation approved by Congress providing for ... in helping to reduce tens of thousands of ... the United States, the National Viral Hepatitis ... was included in the FY 2010 Consolidated Appropriations ...
(Date:12/14/2009)... Federation of America (HFA) expresses its concern regarding ... 929 and the American Red Cross of Pennsylvania ... skilled workers to provide clean, safe blood to ... as clotting factor for use in treating hemophilia ... of Blood Services at the American Red Cross ...
(Date:12/14/2009)... Kurth Krause, an aerospace engineer,for NASA, was giving ... moon, he,was confident that technology and science could ... was one thing that science couldn,t solve.,His wife ... dialysis machines,would keep her alive for awhile, she ... is 69 and is starting dialysis next month. ...
(Date:12/14/2009)... could be linked to scans performed in 2007 , , ... are exposing patients to far more radiation than previously thought ... cancers a year, two new studies claim. , Based on ... Archives of Internal Medicine , the study authors, joined ... calling on clinicians to limit radiation exposure to patients. , ...
(Date:12/14/2009)... , , MONDAY, Dec. 14 (HealthDay News) -- Here,s good ... a cup or two of java: Coffee and tea ... diabetes. , That,s the conclusion of an Australian ... the lower your risk of diabetes. Every cup of ... the risk of diabetes, the researchers said. , ...
Breaking Medicine News(10 mins):Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:HFA Voices Blood Safety Concerns 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3
... the presence of cancer cells beneath layers skin, blood ... bottle-top sized microcavity laser developed by the US department of ... without cutting large amounts of tissue.// ,This device could ... present and was able to distinguish between normal human brain ...
... release about one third the population of Bangladesh are at ... , Drinking arsenic tainted water for prolonged periods results ... bladder said the study.// , At least 100,000 ... World Health Organization report published last September. ,Diagnosis ...
... is effective for another purpose - fighting lymphoma, a ... ,The Scientists from Mayo clinic department of molecular ... remission of lymphoma in mice injected with human cells ... the findings as an early step in potentially developing ...
... that people who tend to get angry showed an increase ... found in blood and strongly associated with coronary heart disease. ... and co-author of this study// states that it is one ... to get heart disease. ,The study measured the levels ...
... elite disease as so much of research are going on ... such ongoing research, hyperhomocysteinemia (increased levels of homocysteine in blood) ... ,Dr. O Mayer Jr and colleagues from Charles University in ... that beer may provide enough folate--a B vitamin that would ...
... type 1 diabetes reveal that they have more chances of ... ,The findings were based on study done on a ... 21 years, without type 1 diabetes. It was found that ... of body weight, family history, smoking and length of time ...
Other Medicine News:
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
Selute Picotip Atrial-J steroid eluting passive fixation lead...
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: